Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease.

Although the switch cohort comprised a smaller number of participants, similar results were observed as with the rollover cohort, except for a slight trend where participants with baseline TMC scores above the median of 12.5 received higher dosages (median dosage, 60 mg/d) to achieve TMC response (Figs. 2 , 3 , 4 ).

also in 4,078 other papers